Search
Adagrasib
go.drugbank.com/drugs/DB15568ApprovedInvestigationalAdagrasib (MRTX849) is an oral, small-molecule KRAS inhibitor developed by Mirati Therapeutics. … KRAS mutations are highly common in cancer and account for approximately 85% of all RAS family mutations.
Fenproporex
go.drugbank.com/drugs/DB01550ApprovedIllicitWithdrawnFenproporex is an orally active stimulant drug, which was developed in the 1960s. It is used as an appetite suppressant and a treatment for obesity. … prescribed in South America.
Atosiban
go.drugbank.com/drugs/DB09059ApprovedInvestigationalIt was first reported in the literature in 1985. Atosiban is licensed in proprietary and generic forms for the delay of imminent pre-term birth in pregnant adult women. … Atosiban is an inhibitor of the hormones oxytocin and vasopressin. It is used intravenously to halt premature labor.
Products: Atosiban Accord 6,75 mg/0,9 ml Injektionslösung in einer FertigspritzeTrichloroacetate
go.drugbank.com/drugs/DB11152ApprovedInvestigationalTrichloroacetate is also found in cosmetic treatments and topical formulations as a cauterant, which removes condyloma or warts on the skin. … In clinical chemistry and biochemistry, it is used as a precipitant of macromolecules including proteins, DNA and RNA.
Categories: Compounds used in a research, industrial, or household settingTyropanoic acid
go.drugbank.com/drugs/DB09340ApprovedThe molecule contains three heavy iodine atoms which obstruct X-rays in the same way as the calcium in bones, which results in a visible image [L1608]. … Tyropanoic acid is a radiocontrast agent used in cholecystography, the X-ray diagnosis of gallstones under the trade names include Bilopaque, Lumopaque, Tyropaque, and Bilopac.
Categories: Compounds used in a research, industrial, or household settingDaratumumab
go.drugbank.com/drugs/DB09331ApprovedInvestigationalIn July 2024, it was further approved in combination with bortezomib, lenalidomide, and dexamethasone (D-VRd) for induction and consolidation therapy in newly diagnosed, transplant-eligible patients. … [A7935] It was first described in the literature in 2010 as a monoclonal antibody that targets CD38+ multiple myeloma cells; the first of its kind.
Estetrol
go.drugbank.com/drugs/DB12235ApprovedInvestigationalEstetrol is the first new estrogen introduced to the USA in over 50 years and is the first approved estetrol product in the world. … [L33179] In Canada, Nextstellis was approved for use in March 2021; it was developed by Mithra and is marketed by Searchlight Pharma.[L33209]
Tezepelumab
go.drugbank.com/drugs/DB15090ApprovedInvestigational[L39504] Tezepelumab was also approved by the European Commission on September 19, 2022.[L44712] … It was granted FDA approval on December 17, 2021, and is currently marketed under the trademark TEZSPIRE by Amgen/AstraZeneca.
Rimegepant
go.drugbank.com/drugs/DB12457ApprovedInvestigationalsafer for use in patients with contraindications to standard therapy. … Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals.
Triclabendazole
go.drugbank.com/drugs/DB12245ApprovedInvestigationalTriclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans. … Triclabendazole was previously used in the treatment of fascioliasis in livestock, but is now approved for human use.